A phase 3 trial of Adapalene/minocycline in subjects with moderate-to-severe acne vulgaris
Latest Information Update: 30 Dec 2020
At a glance
- Drugs Adapalene/minocycline (Primary)
- Indications Acne vulgaris
- Focus Registrational; Therapeutic Use
- Acronyms TRILOGY-1
- Sponsors VYNE Therapeutics
- 17 Dec 2020 According to a VYNE Therapeutics media release, the company is on track to initiate this TRILOGY Phase 3 program in 2021.
- 17 Dec 2020 According to a VYNE Therapeutics media release, based on the results of this phase 2 study, the non-clinical safety and CMC, the company has completed the End-of-Phase 2 Meeting with the USA Food and Drug Administration (FDA). The meeting has provided the clear direction on the Phase 3 clinical and pharmaceutical development plans for FCD105.
- 05 Jun 2020 New trial record